MeiraGTx Holdings plc Finance Lease, Liability
MeiraGTx Holdings plc (MGTX) had Finance Lease, Liability of $125.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Liabilities
us-gaap:FinanceLeaseLiability · last filed 2026-08-13
- 2026-06-30: Finance Lease, Liability $125.00K.
- 2026-03-31: Finance Lease, Liability $136.00K.
- 2025-12-31: Finance Lease, Liability $147.00K.
- 2022-06-30: Finance Lease, Liability $4.00K.
| Period end | Finance Lease, Liability | Finance Lease, Liability as first filed |
|---|---|---|
| 2026-06-30 | $125.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $136.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $147.00K 10-Q · filed 2026-08-13 | |
| 2022-06-30 | $4.00K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $8.00K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $12.00K 10-Q · filed 2022-11-10 | |
| 2021-09-30 | $17.00K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $22.00K 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $25.00K 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $28.00K 10-K · filed 2022-03-10 | $28.32K 10-K · filed 2021-03-11 |
| 2020-09-30 | $30.11K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $32.08K 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $37.91K 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $50.74K 10-K · filed 2021-03-11 | |
| 2019-09-30 | $16.37K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $20.93K 10-Q · filed 2019-08-07 | |
| 2019-03-31 | $27.67K 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |